SemaCyte cell assaying platform

Drug-screening spin-out secures new funding

23 February 2022

A University of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a £2.14 million seed funding round.

Read More

Training a new breed of clinical triallist

03 February 2022

Cambridge's Experimental Medicine Initiative, working with AstraZeneca and GSK, is training specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.

Read More

Pages